Briefing
Capecitabine in ER-positive HER2-negative breast cancer with molecular residual disease
Phase 2 trial whose registry primary outcome is the ctDNA clearance rate at 16 weeks of metronomic capecitabine, measured with the Pathlight assay, in people with molecular residual disease. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting